Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

55.23 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 188
Open 55.23
Bid (Size) 51.60 (12)
Ask (Size) 56.27 (1)
Prev. Close 55.23
Today's Range 55.23 - 55.23
52wk Range 42.51 - 169.76
Shares Outstanding 77,457,081
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Cathie Wood Provides Lesson of the Day: Don't Invest in Fairytale Stocks
Tesla is no longer the No.1 holding of Cathie Wood's ARK. Let's see what's inside. 
Via Talk Markets
Why Orphan Drug Designation Offers Several Benefits
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we... 
Via FinancialNewsMedia
Exposures Product Safety

Performance

YTD
-32.41%
-32.41%
1 Month
+4.60%
+4.60%
3 Month
-3.38%
-3.38%
6 Month
-29.90%
-29.90%
1 Year
-53.40%
-53.40%

More News

Read More
Analyst Ratings for CRISPR Therapeutics
Via Benzinga
How to Buy Stocks in a Recession
Via InvestorPlace
5 Cathie Wood Stocks to Buy Now
Via InvestorPlace
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Via Investor's Business Daily
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
Via Benzinga
$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
What 4 Analyst Ratings Have To Say About CRISPR Therapeutics
Via Benzinga
3 Cathie Wood Stocks to Count on in Q2
Via InvestorPlace
7 Potential Biotech Stocks Buyout Targets in 2022
Via InvestorPlace
$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much
Via Benzinga
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
3 Best Stocks to Trade Right Now
Via InvestorPlace
Fed Rate Hike Rallies Stocks
Via Talk Markets
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
3 Ark Invest Most-Shorted Stocks to Buy
Via InvestorPlace
7 Cathie Wood Stocks That Are Worth Buying in March
Via InvestorPlace
3 Cathie Wood Stocks to Buy
Via InvestorPlace
Tough Slogging Ahead for Investors, Diversification is Important
Via Talk Markets
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
Via Investor's Business Daily
Peloton Isn’t the ONLY Takeover Target. What Companies Could Be Bought Out in 2022?
Via InvestorPlace
Why Jim Cramer Believes Sirius XM Is Inexpensive
Via Benzinga
What Are Whales Doing With CRISPR Therapeutics
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.